ATE555803T1 - Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen - Google Patents
Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungenInfo
- Publication number
- ATE555803T1 ATE555803T1 AT02738042T AT02738042T ATE555803T1 AT E555803 T1 ATE555803 T1 AT E555803T1 AT 02738042 T AT02738042 T AT 02738042T AT 02738042 T AT02738042 T AT 02738042T AT E555803 T1 ATE555803 T1 AT E555803T1
- Authority
- AT
- Austria
- Prior art keywords
- osteopontin
- treat
- neurological diseases
- prevent neurological
- prevent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01111296 | 2001-05-17 | ||
PCT/EP2002/005081 WO2002092122A2 (en) | 2001-05-17 | 2002-05-08 | Use of osteopontin for the treatment and/or prevention of neurologic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE555803T1 true ATE555803T1 (de) | 2012-05-15 |
Family
ID=8177366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02738042T ATE555803T1 (de) | 2001-05-17 | 2002-05-08 | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen |
Country Status (27)
Country | Link |
---|---|
US (4) | US7217687B2 (de) |
EP (1) | EP1389130B1 (de) |
JP (2) | JP4417632B2 (de) |
KR (1) | KR100947424B1 (de) |
CN (2) | CN1286524C (de) |
AT (1) | ATE555803T1 (de) |
AU (1) | AU2002312886B2 (de) |
BG (1) | BG108337A (de) |
BR (1) | BR0209812A (de) |
CA (1) | CA2443964A1 (de) |
CZ (1) | CZ20033109A3 (de) |
EA (1) | EA006655B1 (de) |
EE (1) | EE200300559A (de) |
ES (1) | ES2387082T3 (de) |
HK (1) | HK1067051A1 (de) |
HR (1) | HRP20030840A2 (de) |
HU (1) | HUP0400005A3 (de) |
IL (2) | IL158867A0 (de) |
MX (1) | MXPA03010327A (de) |
NO (1) | NO20035025D0 (de) |
NZ (1) | NZ528852A (de) |
PL (1) | PL211763B1 (de) |
SK (1) | SK14232003A3 (de) |
UA (1) | UA85368C2 (de) |
WO (1) | WO2002092122A2 (de) |
YU (1) | YU89503A (de) |
ZA (1) | ZA200307956B (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005046719A1 (en) * | 2003-11-12 | 2005-05-26 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
WO2002090974A2 (de) * | 2001-05-09 | 2002-11-14 | Biovision Ag | Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien |
AU2002357748A1 (en) | 2001-11-21 | 2003-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Osteopontin-related compositions and methods |
CA2489905A1 (en) * | 2002-06-25 | 2003-12-31 | Aventis Pharmaceuticals Inc. | Osteopontin, oligodendrocytes and myelination |
WO2004013311A2 (en) * | 2002-08-06 | 2004-02-12 | Diadexus, Inc. | Compositions and methods relating to ovarian specific genes and proteins |
KR20050119149A (ko) * | 2003-03-28 | 2005-12-20 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | 말초 신경 질환의 치료 및/또는 예방을 위한 클루스테린의용도 |
RU2379975C2 (ru) * | 2003-09-18 | 2010-01-27 | Арла Фудс Амба | Добавка в состав для детского питания |
US7790687B2 (en) * | 2005-02-18 | 2010-09-07 | Proximagen Ltd. | Treatment for neurodegeneration |
US20060264371A1 (en) * | 2005-02-18 | 2006-11-23 | Proximagen Ltd. | Treatment |
WO2007047465A1 (en) | 2005-10-13 | 2007-04-26 | Anthrogenesis Corporation | Production of oligodendrocytes from placenta-derived stem cells |
EP1870107A1 (de) * | 2006-06-23 | 2007-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verwendung eines PML Auslöser zur Behandlung von neurodegenerativen Krankheiten mit Polyglutamine Vermehrung |
WO2008086449A2 (en) * | 2007-01-09 | 2008-07-17 | Oregon Health & Science University | Synthetic osteopontin peptides and methods of use |
US20100069254A1 (en) * | 2008-09-16 | 2010-03-18 | Laree Hiser | Cell Culture Model for Demyelination/Remyelination |
KR101449100B1 (ko) | 2011-04-21 | 2014-10-13 | 가톨릭대학교 산학협력단 | 신경세포 데브리스 제거용 오스테오폰틴 |
GB2493540A (en) * | 2011-08-10 | 2013-02-13 | Follicum Ab | Agents for stimulating hair growth in mammals |
KR101728808B1 (ko) * | 2012-09-28 | 2017-04-20 | 한국생명공학연구원 | 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물 |
WO2016033329A1 (en) * | 2014-08-27 | 2016-03-03 | Dana-Farber Cancer Institute, Inc. | Intracellular osteopontin regulates the lineage commitment of lymphoid subsets |
KR102425326B1 (ko) | 2016-05-20 | 2022-07-25 | 세다르스-신나이 메디칼 센터 | 알츠하이머병 및 관련 병태의 치료 또는 예방 방법 |
CN109996810B (zh) * | 2016-11-27 | 2023-08-22 | 特里同阿盖亚创新公司 | 从微藻中纯化重组骨桥蛋白的方法 |
WO2018202870A1 (en) | 2017-05-04 | 2018-11-08 | Follicum Ab | Peptides for treatment of diabetes |
US11484576B2 (en) | 2017-08-15 | 2022-11-01 | The Children's Medical Center Corporation | Methods of promoting corticospinal neuronal outgrowth in neuronal lesions using a pro-regenerative human osteopontin fragment |
TR201903865A2 (tr) * | 2019-03-14 | 2020-09-21 | Bogazici Ueniversitesi | Amyotrofi̇k lateral skleroz tedavi̇si̇ i̇çi̇n i̇nterferon kullanimi |
WO2021024265A1 (en) * | 2019-08-08 | 2021-02-11 | Ramot At Tel-Aviv University Ltd. | Methods of treating non-infectious inflammatory disorders |
CN111388654A (zh) * | 2020-05-22 | 2020-07-10 | 南通大学 | 治疗脊髓损伤的药物、药物试剂盒及方法 |
EP4159223A1 (de) * | 2020-06-02 | 2023-04-05 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | Zusammensetzung mit osteopontinhemmer als wirkstoff zur prävention, linderung oder behandlung von neurodegenerativen erkrankungen |
CN117720620A (zh) * | 2023-12-13 | 2024-03-19 | 无锡市儿童医院 | 小分子多肽和其药物组合物、其制药用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69926536T3 (de) * | 1998-12-22 | 2013-09-12 | Genentech, Inc. | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung |
JP2003517284A (ja) | 1999-04-15 | 2003-05-27 | チルドレンズ メディカル センター コーポレーション | 免疫応答を変調する方法及び組成物 |
WO2000064460A2 (en) | 1999-04-23 | 2000-11-02 | Sulzer Orthopedics Ltd. | Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin |
JP4027663B2 (ja) * | 1999-10-04 | 2007-12-26 | ネクター セラピューティックス エイエル,コーポレイション | ポリマー安定化神経ペプチド |
-
2002
- 2002-05-08 CA CA002443964A patent/CA2443964A1/en not_active Abandoned
- 2002-05-08 SK SK1423-2003A patent/SK14232003A3/sk unknown
- 2002-05-08 AU AU2002312886A patent/AU2002312886B2/en not_active Ceased
- 2002-05-08 EE EEP200300559A patent/EE200300559A/xx unknown
- 2002-05-08 EP EP02738042A patent/EP1389130B1/de not_active Expired - Lifetime
- 2002-05-08 EA EA200301253A patent/EA006655B1/ru not_active IP Right Cessation
- 2002-05-08 US US10/477,876 patent/US7217687B2/en not_active Expired - Fee Related
- 2002-05-08 HU HU0400005A patent/HUP0400005A3/hu unknown
- 2002-05-08 PL PL367065A patent/PL211763B1/pl not_active IP Right Cessation
- 2002-05-08 AT AT02738042T patent/ATE555803T1/de active
- 2002-05-08 MX MXPA03010327A patent/MXPA03010327A/es active IP Right Grant
- 2002-05-08 WO PCT/EP2002/005081 patent/WO2002092122A2/en active Application Filing
- 2002-05-08 CN CNB028144627A patent/CN1286524C/zh not_active Expired - Fee Related
- 2002-05-08 KR KR1020037014773A patent/KR100947424B1/ko not_active IP Right Cessation
- 2002-05-08 CN CNA2006101317669A patent/CN1939538A/zh active Pending
- 2002-05-08 CZ CZ20033109A patent/CZ20033109A3/cs unknown
- 2002-05-08 ES ES02738042T patent/ES2387082T3/es not_active Expired - Lifetime
- 2002-05-08 JP JP2002589038A patent/JP4417632B2/ja not_active Expired - Fee Related
- 2002-05-08 NZ NZ528852A patent/NZ528852A/en not_active IP Right Cessation
- 2002-05-08 YU YU89503A patent/YU89503A/sh unknown
- 2002-05-08 BR BR0209812-1A patent/BR0209812A/pt not_active IP Right Cessation
- 2002-05-08 IL IL15886702A patent/IL158867A0/xx unknown
- 2002-05-08 UA UA20031110269A patent/UA85368C2/ru unknown
-
2003
- 2003-10-13 ZA ZA200307956A patent/ZA200307956B/en unknown
- 2003-10-15 HR HR20030840A patent/HRP20030840A2/hr not_active Application Discontinuation
- 2003-11-10 BG BG108337A patent/BG108337A/bg unknown
- 2003-11-12 NO NO20035025A patent/NO20035025D0/no not_active Application Discontinuation
- 2003-11-13 IL IL158867A patent/IL158867A/en not_active IP Right Cessation
-
2004
- 2004-11-05 US US10/981,737 patent/US7297099B2/en not_active Expired - Fee Related
- 2004-12-22 HK HK04110138A patent/HK1067051A1/xx not_active IP Right Cessation
-
2007
- 2007-02-27 US US11/679,735 patent/US20070225214A1/en not_active Abandoned
- 2007-11-07 US US11/936,623 patent/US20080213234A1/en not_active Abandoned
-
2009
- 2009-06-05 JP JP2009136621A patent/JP5036761B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE555803T1 (de) | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen | |
DE60133029D1 (de) | Mittel zur prävention oder behandlung von psoriasi | |
DE60324777D1 (de) | Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten | |
DE69936335D1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
NO20054913L (no) | Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser | |
CY1107439T1 (el) | Μεθοδοι προληψης και θεραπειας μολυνσης απο ιο του γενους flavivirus σε ζωα | |
ATE362374T1 (de) | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust | |
ATE361745T1 (de) | Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen | |
ATE369130T1 (de) | Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen | |
DE60219687D1 (de) | Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems | |
DE60224004D1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten | |
DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
ATE346597T1 (de) | Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten | |
ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
ATE427754T1 (de) | Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen | |
DE60231994D1 (de) | Mittel zur behandlung oder prävention allergischerg | |
DE69936779D1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
ATE360425T1 (de) | Verwendung von quetiapin für die behandlung von kokain-abhängigkeit | |
ATE314066T1 (de) | Verwendung von buprenorphin zur therapie der harninkontinenz | |
DE69919578D1 (de) | VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten | |
ATE384520T1 (de) | Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitas | |
ATE275949T1 (de) | Verwendung von diminazen-di-aceturat und/oder pentamidin zur behandlung von malaria | |
ATE311901T1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
ATE291434T1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
ATE286390T1 (de) | Felabamat-derivate zur behandlung von neuropathischem schmerz |